BioSpace News Archive

The Second Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program Will Provide Funding for Up To Eight Research Projects With Individual Grant Amounts of Up To $100,000 per Project

Enzyvant announced that its investigational regenerative treatment in late-stage development for congenital athymia will be featured during a platform presentation, at a symposium, and in a poster session at the Clinical Immunology Society 2019 annual meeting in Atlanta, GA, April 4-7.

CTI BioPharma Corp. announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central.

Immunocore Limited announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its development program, the investigation of tebentafusp for the treatment of patients who are HLA-A*0201-positive with previously untreated, metastatic uveal melanoma.

Access Industries announced the appointment of Dr. Liam Ratcliffe to head Access Biotechnology, a newly formed strategic investment arm specializing in therapeutic platforms and products.

Calliditas Therapeutics AB announced that Renée Aguiar-Lucander, the company’s Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 9, 2019 at 4:10 p.m. ET at the Westin Grand Central Hotel in New York City.

Moleculin Biotech, Inc. announced that preclinical data supporting activity of its STAT3-inhibiting Immune/Transcription Modulators was presented by Dr. Waldemar Priebe, Founder and Chair of the Scientific Advisory Board of Moleculin, Inc. at the 2019 Annual Meeting of the American Association for Cancer Research (“AACR”) in Atlanta, GA.

Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $4.00 per share.

Oak Street Health, a network of centers that provide innovative primary care services to Medicare recipients, will bring a uniquely holistic healthcare option to Flint, Michigan with two centers in 2019.

Studies observed increase in double-stranded DNA breaks and reduction in MCL-1 levels in cell lines resistant to venetoclax following Actimab exposure